Jefferies Financial Group Upgrades AdaptHealth (NASDAQ:AHCO) to “Buy”

AdaptHealth (NASDAQ:AHCO) was upgraded by equities research analysts at Jefferies Financial Group from a “hold” rating to a “buy” rating in a research note issued on Tuesday,Benzinga reports. The brokerage presently has a $13.00 price target on the stock, up from their prior price target of $11.00. Jefferies Financial Group’s price objective suggests a potential upside of 18.40% from the company’s current price.

A number of other research analysts also recently weighed in on the company. Royal Bank Of Canada upped their target price on AdaptHealth from $13.00 to $15.00 and gave the stock an “outperform” rating in a report on Monday, May 11th. UBS Group lowered their price objective on AdaptHealth from $15.00 to $14.00 and set a “buy” rating for the company in a research report on Wednesday, May 6th. Canaccord Genuity Group upped their target price on shares of AdaptHealth from $14.00 to $16.00 and gave the stock a “buy” rating in a research report on Wednesday, May 6th. Weiss Ratings reissued a “sell (d)” rating on shares of AdaptHealth in a research note on Friday, May 22nd. Finally, Truist Financial boosted their price target on AdaptHealth from $13.00 to $14.00 and gave the stock a “buy” rating in a research report on Monday, April 13th. Seven research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the company’s stock. According to MarketBeat, the company currently has a consensus rating of “Moderate Buy” and a consensus target price of $14.14.

AdaptHealth Trading Up 0.2%

NASDAQ:AHCO opened at $10.98 on Tuesday. The company has a 50-day moving average price of $10.25 and a 200-day moving average price of $10.63. The stock has a market cap of $1.49 billion, a price-to-earnings ratio of -17.71, a P/E/G ratio of 0.56 and a beta of 1.45. The company has a current ratio of 0.92, a quick ratio of 0.71 and a debt-to-equity ratio of 1.21. AdaptHealth has a 12 month low of $8.51 and a 12 month high of $13.43.

Insider Buying and Selling at AdaptHealth

In related news, insider Russell E. Schuster III sold 11,275 shares of the business’s stock in a transaction that occurred on Monday, June 1st. The shares were sold at an average price of $10.06, for a total transaction of $113,426.50. Following the completion of the sale, the insider directly owned 136,538 shares in the company, valued at approximately $1,373,572.28. The trade was a 7.63% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. 1.95% of the stock is owned by company insiders.

Institutional Inflows and Outflows

A number of hedge funds have recently made changes to their positions in the stock. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. raised its position in shares of AdaptHealth by 4.4% during the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 60,495 shares of the company’s stock valued at $656,000 after purchasing an additional 2,564 shares during the period. Goldman Sachs Group Inc. raised its position in shares of AdaptHealth by 32.4% during the first quarter. Goldman Sachs Group Inc. now owns 571,232 shares of the company’s stock valued at $6,192,000 after buying an additional 139,828 shares during the last quarter. Woodline Partners LP purchased a new position in AdaptHealth during the first quarter valued at $2,851,000. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC boosted its holdings in shares of AdaptHealth by 18.1% during the 1st quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 233,780 shares of the company’s stock valued at $2,534,000 after purchasing an additional 35,879 shares during the last quarter. Finally, JPMorgan Chase & Co. increased its holdings in shares of AdaptHealth by 1.3% in the second quarter. JPMorgan Chase & Co. now owns 211,769 shares of the company’s stock worth $1,997,000 after purchasing an additional 2,718 shares during the last quarter. 82.67% of the stock is currently owned by institutional investors.

About AdaptHealth

AdaptHealth, Inc operates as a leading provider of home medical equipment (HME) and related services in the United States. The company focuses on delivering respiratory care, mobility solutions and bathroom safety products to patients with chronic and acute medical needs. Through its comprehensive service offerings, AdaptHealth aims to enhance quality of life and clinical outcomes for patients who require long-term support outside of a hospital setting.

The company’s respiratory portfolio includes products such as continuous positive airway pressure (CPAP) devices, oxygen concentrators, ventilators, and associated supplies for patients with sleep apnea, COPD and other pulmonary conditions.